Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant High Dose Vitamin A for Resectable NSCLC
NCT03870529Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vitamin a in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Presence or Absence of Germinal Centers in Resected Tissue up to 2 years. Started Aug 2019; status: terminated.
02
Drugs
vitamin a
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03870529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870529.